Dendritic cells in melanoma immunotherapy.
No consensus exists regarding optimal systemic treatment for melanoma in the adjuvant or metastatic disease setting. Dendritic cell vaccine therapy, though investigational at present, offers very promising preliminary data that warrant exploration, and patients with existing disease and those seeking adjuvant treatment should evaluate open protocols using this strategy.
Faries
Mark B
MB
Department of Surgery, University of Pennsylvania, 4 Silverstein, 3400 Spruce St., Philadelphia, PA 19104, USA.
Czerniecki
Brian J
BJ
D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000637:transplantation*; D006801:Humans; D016219:Immunotherapy, Adoptive; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D012878:Skin Neoplasms / Q000628:therapy*; D014162:Transfection
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines